Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $76861.0.

  • Aligos Therapeutics' Treasury Shares rose 163540.3% to $76861.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76861.0, marking a year-over-year increase of 163540.3%. This contributed to the annual value of $4729.0 for FY2024, which is 1180.53% down from last year.
  • Latest data reveals that Aligos Therapeutics reported Treasury Shares of $76861.0 as of Q3 2025, which was up 163540.3% from $17264.0 recorded in Q2 2025.
  • Aligos Therapeutics' 5-year Treasury Shares high stood at $303711.0 for Q1 2021, and its period low was $3717.0 during Q2 2022.
  • Over the past 5 years, Aligos Therapeutics' median Treasury Shares value was $76861.0 (recorded in 2025), while the average stood at $91235.1.
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 9834.59% in 2022, then soared by 163540.3% in 2025.
  • Aligos Therapeutics' Treasury Shares (Quarter) stood at $89054.0 in 2021, then plummeted by 95.83% to $3717.0 in 2022, then surged by 44.26% to $5362.0 in 2023, then decreased by 11.81% to $4729.0 in 2024, then soared by 1525.31% to $76861.0 in 2025.
  • Its last three reported values are $76861.0 in Q3 2025, $17264.0 for Q2 2025, and $17264.0 during Q1 2025.